A Meta-Analysis of Memantine for Depression

Taro Kishi, Shinji Matsunaga, Nakao Iwata

Research output: Contribution to journalArticle

5 Citations (Scopus)

Abstract

We conducted a systematic review and meta-analysis on whether memantine was beneficial for the treatment of depressive symptoms in major depressive disorder (MDD) and bipolar disorder (BD). The analysis included double-blind, randomized, placebo-controlled trials of memantine in MDD and BD. The primary outcome measures for efficacy and safety were response rate and all-cause discontinuation, respectively. Risk ratio (RR) and standardized mean difference with 95 confidence intervals (95 CI) were calculated. We identified six trials including 451 patients: MDD, four trials (n = 189), three of which studied memantine augmentation for antidepressants; BD, two trials (n = 262), both on memantine augmentation for mood stabilizers. The mean study duration was 8.33 weeks, and the mean age of patients was 39.9 years. Memantine was not superior to placebo with regard to response rate (RR = 0.92, 95 CI = 0.70-1.20, I2 = 72), remission rate, improvement of depressive symptoms scale score, all-cause discontinuation (RR = 0.84, 95 CI = 0.60-1.18, I2 = 0), discontinuation due to inefficacy and adverse events, or incidence of individual adverse events including decreased appetite, dizziness, nausea, and sedation. Although we conducted sensitivity analyses of the response rate to determine the reasons for the heterogeneity (diagnosis, age of patients, memantine dose, memantine augmentation, geographical region, and statistical population), we did not seek confounding factors. Memantine did not improve the treatment efficacy for depressive symptoms in MDD and BD patients. Long-term study of memantine for depression is required.

Original languageEnglish
Pages (from-to)113-121
Number of pages9
JournalJournal of Alzheimer's Disease
Volume57
Issue number1
DOIs
Publication statusPublished - 01-01-2017

Fingerprint

Memantine
Meta-Analysis
Depression
Major Depressive Disorder
Bipolar Disorder
Odds Ratio
Confidence Intervals
Placebos
Dizziness
Appetite
Nausea
Antidepressive Agents
Randomized Controlled Trials
Outcome Assessment (Health Care)
Safety

All Science Journal Classification (ASJC) codes

  • Neuroscience(all)
  • Clinical Psychology
  • Geriatrics and Gerontology
  • Psychiatry and Mental health

Cite this

Kishi, Taro ; Matsunaga, Shinji ; Iwata, Nakao. / A Meta-Analysis of Memantine for Depression. In: Journal of Alzheimer's Disease. 2017 ; Vol. 57, No. 1. pp. 113-121.
@article{b95111e2642b41ae800f40abdc6dc327,
title = "A Meta-Analysis of Memantine for Depression",
abstract = "We conducted a systematic review and meta-analysis on whether memantine was beneficial for the treatment of depressive symptoms in major depressive disorder (MDD) and bipolar disorder (BD). The analysis included double-blind, randomized, placebo-controlled trials of memantine in MDD and BD. The primary outcome measures for efficacy and safety were response rate and all-cause discontinuation, respectively. Risk ratio (RR) and standardized mean difference with 95 confidence intervals (95 CI) were calculated. We identified six trials including 451 patients: MDD, four trials (n = 189), three of which studied memantine augmentation for antidepressants; BD, two trials (n = 262), both on memantine augmentation for mood stabilizers. The mean study duration was 8.33 weeks, and the mean age of patients was 39.9 years. Memantine was not superior to placebo with regard to response rate (RR = 0.92, 95 CI = 0.70-1.20, I2 = 72), remission rate, improvement of depressive symptoms scale score, all-cause discontinuation (RR = 0.84, 95 CI = 0.60-1.18, I2 = 0), discontinuation due to inefficacy and adverse events, or incidence of individual adverse events including decreased appetite, dizziness, nausea, and sedation. Although we conducted sensitivity analyses of the response rate to determine the reasons for the heterogeneity (diagnosis, age of patients, memantine dose, memantine augmentation, geographical region, and statistical population), we did not seek confounding factors. Memantine did not improve the treatment efficacy for depressive symptoms in MDD and BD patients. Long-term study of memantine for depression is required.",
author = "Taro Kishi and Shinji Matsunaga and Nakao Iwata",
year = "2017",
month = "1",
day = "1",
doi = "10.3233/JAD-161251",
language = "English",
volume = "57",
pages = "113--121",
journal = "Journal of Alzheimer's Disease",
issn = "1387-2877",
publisher = "IOS Press",
number = "1",

}

A Meta-Analysis of Memantine for Depression. / Kishi, Taro; Matsunaga, Shinji; Iwata, Nakao.

In: Journal of Alzheimer's Disease, Vol. 57, No. 1, 01.01.2017, p. 113-121.

Research output: Contribution to journalArticle

TY - JOUR

T1 - A Meta-Analysis of Memantine for Depression

AU - Kishi, Taro

AU - Matsunaga, Shinji

AU - Iwata, Nakao

PY - 2017/1/1

Y1 - 2017/1/1

N2 - We conducted a systematic review and meta-analysis on whether memantine was beneficial for the treatment of depressive symptoms in major depressive disorder (MDD) and bipolar disorder (BD). The analysis included double-blind, randomized, placebo-controlled trials of memantine in MDD and BD. The primary outcome measures for efficacy and safety were response rate and all-cause discontinuation, respectively. Risk ratio (RR) and standardized mean difference with 95 confidence intervals (95 CI) were calculated. We identified six trials including 451 patients: MDD, four trials (n = 189), three of which studied memantine augmentation for antidepressants; BD, two trials (n = 262), both on memantine augmentation for mood stabilizers. The mean study duration was 8.33 weeks, and the mean age of patients was 39.9 years. Memantine was not superior to placebo with regard to response rate (RR = 0.92, 95 CI = 0.70-1.20, I2 = 72), remission rate, improvement of depressive symptoms scale score, all-cause discontinuation (RR = 0.84, 95 CI = 0.60-1.18, I2 = 0), discontinuation due to inefficacy and adverse events, or incidence of individual adverse events including decreased appetite, dizziness, nausea, and sedation. Although we conducted sensitivity analyses of the response rate to determine the reasons for the heterogeneity (diagnosis, age of patients, memantine dose, memantine augmentation, geographical region, and statistical population), we did not seek confounding factors. Memantine did not improve the treatment efficacy for depressive symptoms in MDD and BD patients. Long-term study of memantine for depression is required.

AB - We conducted a systematic review and meta-analysis on whether memantine was beneficial for the treatment of depressive symptoms in major depressive disorder (MDD) and bipolar disorder (BD). The analysis included double-blind, randomized, placebo-controlled trials of memantine in MDD and BD. The primary outcome measures for efficacy and safety were response rate and all-cause discontinuation, respectively. Risk ratio (RR) and standardized mean difference with 95 confidence intervals (95 CI) were calculated. We identified six trials including 451 patients: MDD, four trials (n = 189), three of which studied memantine augmentation for antidepressants; BD, two trials (n = 262), both on memantine augmentation for mood stabilizers. The mean study duration was 8.33 weeks, and the mean age of patients was 39.9 years. Memantine was not superior to placebo with regard to response rate (RR = 0.92, 95 CI = 0.70-1.20, I2 = 72), remission rate, improvement of depressive symptoms scale score, all-cause discontinuation (RR = 0.84, 95 CI = 0.60-1.18, I2 = 0), discontinuation due to inefficacy and adverse events, or incidence of individual adverse events including decreased appetite, dizziness, nausea, and sedation. Although we conducted sensitivity analyses of the response rate to determine the reasons for the heterogeneity (diagnosis, age of patients, memantine dose, memantine augmentation, geographical region, and statistical population), we did not seek confounding factors. Memantine did not improve the treatment efficacy for depressive symptoms in MDD and BD patients. Long-term study of memantine for depression is required.

UR - http://www.scopus.com/inward/record.url?scp=85015195711&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85015195711&partnerID=8YFLogxK

U2 - 10.3233/JAD-161251

DO - 10.3233/JAD-161251

M3 - Article

C2 - 28222534

AN - SCOPUS:85015195711

VL - 57

SP - 113

EP - 121

JO - Journal of Alzheimer's Disease

JF - Journal of Alzheimer's Disease

SN - 1387-2877

IS - 1

ER -